The comparison of the antihypertensive efficacy and tolerability between valsartan plus hydrochlorothiazide 80mg/12.5mg and amlodipine 5mg in the essential hypertensive patients

Trial Profile

The comparison of the antihypertensive efficacy and tolerability between valsartan plus hydrochlorothiazide 80mg/12.5mg and amlodipine 5mg in the essential hypertensive patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Aug 2008

At a glance

  • Drugs Amlodipine; Valsartan/hydrochlorothiazide
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 21 Aug 2008 Actual end date (Sep 2007) added as reported by ClinicalTrials.gov.
    • 21 Aug 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Sep 2007 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top